key: cord-0726034-yk7h6ixq
authors: Fukuda, Asami; Toyoshima, Shota; Yamada, Shiho; Kurosawa, Yusuke; Okayama, Yoshimichi; Maruoka, Shuichiro; Gon, Yasuhiro
title: Enzymatic activity of ACE2 regulates type 2 airway inflammation in mice
date: 2021-03-02
journal: Allergy
DOI: 10.1111/all.14754
sha: 80b9159519a36e649c5b44caeab058661910df0a
doc_id: 726034
cord_uid: yk7h6ixq

nan

To the Editor:

Coronavirus disease 2019 (COVID-19), caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a global pandemic. SARS-CoV-2 spike protein binds to angiotensinconverting enzyme 2 (ACE2), a transmembrane endopeptidase on host cells of the airway epithelium surface for invasion and infection 1 ; therefore, most COVID-19 research has focused on ACE2.

Patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis are reportedly at a high risk of COVID-19 morbidity and mortality, 2,3 regardless of whether they have asthma. 4 Asthma is a heterogeneous disease triggered by environmental factors such as house dust mites (HDM) and viruses that cause chronic airway inflammation. 5 These factors promote epithelial cell damage, leading to the release of cytokines that provoke a type 2 (T2) inflammatory response. 6 ACE2 is not only a receptor for SARS-CoV-2 but also the main enzyme for catalyzing the conversion of angiotensin II into angiotensin (1-7) and exerts anti-inflammatory effects in cardiovascular diseases. 10 However, the relationship between asthma-related allergic inflammation and ACE2 enzymatic activity, but not its expression in the airway, has not been assessed in vivo.

To explore these associations, we used an HDM-induced asthma mouse model, which is T2 dominant asthma model. C57BL/6 J mice were intratracheally exposed or not to HDM (10-15 mice/group) at days 0, 7, and 14. Bronchoalveolar lavage fluid (BALF) and lung tissue samples were harvested at days 3, 10, and 17 to count eosinophils and measure Ace2 expression ( Figure 1A , Appendix S1). (Figure 1D , p < .0001). In contrast, expression levels of the SARS-CoV-2 associated proteases TMPRSS2 and FURIN in the lungs of HDM-treated mice did not significantly differ compared to those in control mice ( Figure 1E and F, Appendix S1). These results indicate that ACE2 expression and/or function is associated with the pathogenesis of allergic airway inflammation.

We next investigated whether ACE2 enzymatic activity can modulate T2 inflammation in asthma. We used diminazene aceturate (DIZE), an activator of ACE2, which was reported by Dhawale et al 12 to attenuate OVA-induced allergic airway inflammation in rats. We injected HDM-induced asthma mice and examined its impact on airway inflammation (Figure 2A ). DIZE treatment did not impact Ace2 expression ( Figure 2B , Appendix S1), whereas its enzymatic activity was significantly elevated( Figure 2C , Appendix S1, p = .0418). DIZE also significantly prevented eosinophilia induced by HDM exposure (Figure 2D The IFNγ concentration in the lung was significantly increased by DIZE treatment ( Figure 2G , Appendix S1, p = .0047). These results suggest that ACE2 expression and its enzymatic activity can regulate T2 allergic airway inflammation in asthma. Interestingly, reduced IL-13 levels in the BALF did not impact Ace2 expression in the lungs of this asthma model. IFNγ reportedly enhances ACE2 expression in human nasal epithelial cells. 8 IFNs and T-cell-activating factors linked with ACE2 expression have been reported as therapeutic targets for patients with T2 inflammation-low asthma suffering from COVID-19. 9 In contrast, IFNs (eg, IFNβ, IFNγ, and IFN-λ1) did not influence ACE2 expression in human bronchial epithelial cells. 13 In our animal model of asthma using HDM, the elevated IFNγ concentration in the lungs of DIZE-treated asthma mice may not upregulate ACE2 expression in lung epithelial cells.

IL-33 is released by the lung epithelia and evokes T2 cytokine production by group 2 innate lymphoid cells (ILC2). 6 As DIZE treatment significantly reduced the IL-33 concentration in the lung, DIZE may inhibit IL-33 production of lung epithelial cells, leading to suppression of ILC2-mediated cytokine release. We speculate that suppression of IL-13 by asthma treatment cancels any resistance against SARS-CoV-2 infection by reducing ACE2 enzymatic activity. Our findings suggest that potentiation of ACE2 enzymatic activity can prevent asthma-associated T2 allergic airway inflammation without affecting Ace2 expression in the lungs. This effect provides new possibilities for treating patients with asthma and COVID-19. However, treatment with DIZE has been shown to cause brain damage in dogs and camels, but not in cattle, rats, or mice. Patients with trypanosomiasis treated with DIZE showed no adverse effects. 14 Further investigations are required to clarify whether DIZE is suitable for treating asthma in humans based on its adverse effect, asthmatic phenotype, and molecular targets of 

SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function

Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Does asthma affect morbidity or severity of COVID-19?

After asthma: redefining airways diseases

Type 2 immunity in the skin and lungs

Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells

Distinct expression of SARS-CoV-2 receptor ACE2 correlates with endotypes of chronic rhinosinusitis with nasal polyps

Expression of SARS-CoV-2 receptor ACE2 and coincident host response signature varies by asthma inflammatory phenotype

The renin-angiotensin system: going beyond the classical paradigms

Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2

Activation of angiotensin-converting enzyme 2 (ACE2) attenuates allergic airway inflammation in rat asthma model

Antiviral activity of Type I, II, and III interferons counterbalances ACE2 inducibility and restricts SARS-CoV-2

The potential actions of angiotensin-converting enzyme II (ACE2) activator diminazene aceturate (DIZE) in various diseases